Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.

被引：0
|
作者：
Aran, Dvir
Granot-Hershkovitz, Einat
Amar-Farkash, Shlomit
Rosenberg-Katz, Keren
机构：
[1] Technion Israel Inst Technol, Fac Biol, Haifa, Israel
[2] Carelon Digital Platforms, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4532
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P plus A) or ipilimumab plus nivolumab (I plus N).
    Shah, Neil J.
    Shinde, Reshma
    Moore, Kristin
    Sainski-Nguyen, Amy
    Le, Lisa
    Cao, Feng
    Song, Rui
    Singhal, Puneet
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck-Reply
    Harrington, Kevin J.
    Haddad, Robert
    JAMA ONCOLOGY, 2024, 10 (01) : 144 - 145
  • [33] A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
    McGregor, Bradley
    Geynisman, Daniel M.
    Burotto, Mauricio
    Suarez, Cristina
    Bourlon, Maria T.
    Barata, Pedro C.
    Gulati, Shuchi
    Huo, Stephen
    Ejzykowicz, Flavia
    Blum, Steven I.
    Del Tejo, Viviana
    Hamilton, Melissa
    May, Jessica R.
    Du, Ella X.
    Wu, Aozhou
    Kral, Pavol
    Ivanescu, Cristina
    Chin, Andi
    Betts, Keith A.
    Lee, Chung-Han
    Choueiri, Toni K.
    Cella, David
    Porta, Camillo
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (03): : 339 - 348
  • [34] Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
    Du, Ella Xiaoyan
    Betts, Keith A.
    Wang, Travis
    Kitchen, Sophie A.
    He, Xuanhao
    Yin, Xin
    Guttenplan, Sarah B.
    Beauchamp, Karen
    Delgado, Andrew
    Rosenblatt, Lisa
    ONCOLOGY AND THERAPY, 2024, 12 (04) : 735 - 751
  • [35] Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients
    Ohba, Kojiro
    Nakanishi, Hiromi
    Kawada, Ken
    Nakamura, Yuichiro
    Mitsunari, Kensuke
    Matsuo, Tomohiro
    Mochizuki, Yasushi
    Imamura, Ryoichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (07) : 827 - 832
  • [36] Enhancing the Immunogenicity of Nivolumab plus Ipilimumab with Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma
    Zarrabi, Kevin K.
    Vaishampayan, Ulka
    Barata, Pedro C.
    EUROPEAN UROLOGY FOCUS, 2024, 10 (06): : 879 - 881
  • [37] Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma
    Kobari, Yuki
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kondo, Tsunenori
    Ishida, Hideki
    Tanabe, Kazunari
    Takagi, Toshio
    IN VIVO, 2021, 35 (06): : 3585 - 3589
  • [38] KEYNOTE-426 Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
    Bedke, J.
    Stuehler, V.
    UROLOGE, 2020, 59 (07): : 841 - 842
  • [39] Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
    Doshi, Gurjyot K.
    Osterland, Andrew J.
    Shi, Ping
    Yim, Annette
    Del Tejo, Viviana
    Guttenplan, Sarah B.
    Eiffert, Samantha
    Yin, Xin
    Rosenblatt, Lisa
    Conkling, Paul R.
    JCO CLINICAL CANCER INFORMATICS, 2024, 8
  • [40] Body composition in patients with metastatic renal cell carcinoma receiving ipilimumab plus nivolumab.
    Dzimitrowicz, Hannah Elizabeth
    Schwartz, Fides
    Infield, Jordan
    Zhang, Dylan
    Ho, Ethan
    Wu, Yuan
    Gupta, Rajan T.
    Harrison, Michael Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16517 - E16517
12345